ACM
ARRY

Asymmetry Capital Management’s Array Biopharma Inc ARRY Stock Holding History

Asymmetry Capital Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-81,649
Closed -$1.33M – 48
2018
Q1 		$1.33M Buy
81,649
+15,554
+24% +$249K 1.67% 22
2017
Q4 		$846K Buy
+66,095
New +$752K 1.15% 24

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Asymmetry Capital Management's ARRY Position: Q2 2018 in Review

Asymmetry Capital Management sold out of Array Biopharma Inc (ARRY) in Q2 2018, closing a stake of 81,649 shares — an estimated $1.33M sold.

Asymmetry Capital Management first reported a position in ARRY in Q4 2017 and held it in 2 quarters. The position peaked at $1.33M in Q1 2018. 223 funds tracked by Wall St. Rank hold ARRY as of Q2 2018.

  • Asymmetry Capital Management reported no remaining Array Biopharma Inc position as of Q2 2018 after selling out during the quarter.
  • Asymmetry Capital Management sold 81,649 Array Biopharma Inc shares in Q2 2018, an estimated $1.33M.
  • Asymmetry Capital Management first reported a position in Array Biopharma Inc in Q4 2017 and held it in 2 quarters.
  • Asymmetry Capital Management's Array Biopharma Inc position peaked at $1.33M in Q1 2018.
  • 223 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2018.

Based on Asymmetry Capital Management's 13F filing for Q2 2018, filed 7 Aug 2018.